FDANews
FDAnews Device Daily Bulletin

NICE Backs electroCore’s gammaCore for Migraines

April 4, 2016

UK’s National Institute of Health and Care Excellence has issued guidance backing electroCore’s vagus nerve stimulation treatment gammaCore, intended to acutely treat migraine and cluster headaches.

The guidance noted five clinical trials in which patients experienced “substantial and meaningful benefit” from treatment.

The CE-marked device is placed on the side of the neck over the vagus nerve, which is stimulated for two minutes. Treatment can last between four and six minutes and the device poses no serious side effects. — Anisa Jibrell